Angiogenesis in the central nervous system

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 489-504

  De Almodovar, Carmen Ruiz ^a   Zacchigna, Serena ^a   Carmeliet, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

blood brain barrrier; CNS disorders; CNS genetic diseasess; CNS tumors; CNS vascularization; ephrinB2

Indexed keywords

EID: 84865111554     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_42     Document Type: Chapter

References (202)

1. Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626): 671-4.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-60.
3. Kurz H. Physiology of angiogenesis. J Neurooncol 2000;50 (1-2):17-35.
4. Noden DM. Embryonic origins and assembly of blood vessels. Am Rev Respir Dis 1989;140(4):1097-103.
5. Ambler CA, Nowicki JL, Burke AC, Bautch VL. Assembly of trunk and limb blood vessels involves extensive migration and vasculogenesis of somite-derived angioblasts. Dev Biol 2001;234(2):352-64.
6. Ambler CA, Schmunk GM, Bautch VL. Stem cell-derived endothelial cells/progenitors migrate and pattern in the embryo using the VEGF signaling pathway. Dev Biol 2003;257(1): 205-19.
7. Hogan KA, Ambler CA, Chapman DL, Bautch VL. The neural tube patterns vessels developmentally using the VEGF signaling pathway. Development 2004;131(7):1503-13.
8. Childs S, Chen JN, Garrity DM, Fishman MC. Patterning of angiogenesis in the zebrafish embryo. Development 2002;129(4):973-82.
9. Chapman DL, Papaioannou VE. Three neural tubes in mouse embryos with mutations in the T-box gene Tbx6. Nature 1998;391(6668):695-7.
10. Kurz H, Gartner T, Eggli PS, Christ B. First blood vessels in the avian neural tube are formed by a combination of dorsal angio-blast immigration and ventral sprouting of endothelial cells. Dev Biol 1996;173(1):133-47.
11. Bar T. The vascular system of the cerebral cortex. Adv Anat Embryol Cell Biol 1980;59:I-VI,1-62.
12. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005;438(7070):954-9.
13. Nagase T, Nagase M, Yoshimura K, Fujita T, Koshima I. Angio-genesis within the developing mouse neural tube is dependent on sonic hedgehog signaling: possible roles of motor neurons. Genes Cells 2005;10(6):595-604.
14. Lawson ND, Vogel AM, Weinstein BM. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 2002;3(1):127-36.
15. Rowitch DH, B SJ, Lee SM, Flax JD, Snyder EY, McMahon AP. Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci 1999;19(20):8954-65.
16. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001;7(6):706-11.
17. Raab S, Beck H, Gaumann A, et al. Impaired brain angiogen-esis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 2004;91(3):595-605.
18. Yamada T, Pfaff SL, Edlund T, Jessell TM. Control of cell pattern in the neural tube: motor neuron induction by diffusible factors from notochord and floor plate. Cell 1993;73(4): 673-86.
19. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376(6535):70-4.
20. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93(5):741-53.
21. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992;114(2): 521-32.
22. Virgintino D, Errede M, Robertson D, Girolamo F, Masciandaro A, Bertossi M. VEGF expression is developmentally regulated during human brain angiogenesis. Histochem Cell Biol 2003;119(3):227-32.
23. Harrigan MR. Angiogenic factors in the central nervous system. Neurosurgery 2003;53(3):639-60; discussion 60-1.
24. Acker T, Beck H, Plate KH. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and-2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev 2001;108(1-2):45-57.
25. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002;16(20): 2684-98.
26. Haigh JJ, Morelli PI, Gerhardt H, et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol 2003;262(2):225-41.
27. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999;126(21):4895-902.
28. Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 2004;231(3):503-9.
29. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vascu-logenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998;95(4):507-19.
30. McCarty JH, Lacy-Hulbert A, Charest A, et al. Selective ablation of alphav integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development 2005;132(1):165-76.
31. Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, Reichardt LF. beta8 integrins are required for vascular morphogenesis in mouse embryos. Development 2002;129(12):2891-903.
32. McCarty JH, Monahan-Earley RA, Brown LF, et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol 2002;22(21):7667-77.
33. Proctor JM, Zang K, Wang D, Wang R, Reichardt LF. Vascular development of the brain requires beta8 integrin expression in the neuroepithelium. J Neurosci 2005;25(43):9940-8.
34. Calderwood DA. Integrin activation. J Cell Sci 2004;117 (Pt 5):657-66.
35. Huang XZ, Wu JF, Cass D, et al. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J Cell Biol 1996;133(4): 921-8.
36. Graus-Porta D, Blaess S, Senften M, et al. Beta1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron 2001;31(3):367-79.
37. Lindahl P, Hellstrom M, Kalen M, Betsholtz C. Endothelial-peri-vascular cell signaling in vascular development: lessons from knockout mice. Curr Opin Lipidol 1998;9(5):407-11.
38. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277(5323):242-5.
39. Milner R, Campbell IL. Developmental regulation of beta1 integrins during angiogenesis in the central nervous system. Mol Cell Neurosci 2002;20(4):616-26.
40. Wang J, Milner R. Fibronectin promotes brain capillary endo-thelial cell survival and proliferation through alpha5beta1 and alphavbeta3 integrins via MAP kinase signalling. J Neurochem 2006;96(1):148-59.
41. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003;61:39-78.
42. Bauer HC, Bauer H. Neural induction of the blood-brain barrier: still an enigma. Cell Mol Neurobiol 2000;20(1):13-28.
43. Kim JH, Kim JH, Park JA, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006;39(4):339-45.
44. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002;38(6):323-37.
45. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7(1):41-53.
46. Reuss B, Dono R, Unsicker K. Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. J Neu-rosci 2003;23(16):6404-12.
47. Reuss B, von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 2003;313(2):139-57.
48. Lee SW, Kim WJ, Choi YK, et al. SSeCKS regulates angiogen-esis and tight junction formation in blood-brain barrier. Nat Med 2003;9(7):900-6.
49. Mi H, Haeberle H, Barres BA. Induction of astrocyte differentiation by endothelial cells. J Neurosci 2001;21(5): 1538-47.
50. Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 2004;89(2): 503-13.
51. Dohgu S, Takata F, Yamauchi A, et al. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res 2005;1038(2):208-15.
52. Schiera G, Bono E, Raffa MP, et al. Synergistic effects of neurons and astrocytes on the differentiation of brain capillary endothelial cells in culture. J Cell Mol Med 2003;7(2): 165-70.
53. Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 2004;78(3):715-21.
54. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007;10(2):103-17.
55. Tournier-Lasserve E. New players in the genetics of stroke. N Engl J Med 2002;347(21):1711-2.
56. Verreault S, Joutel A, Riant F, et al. A novel hereditary small vessel disease of the brain. Ann Neurol 2006;59(2):353-7.
57. Low WC, Junna M, Borjesson-Hanson A, et al. Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. Brain 2007;130(Pt 2): 357-67.
58. Tournier-Lasserve E, Joutel A, Melki J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoen-cephalopathy maps to chromosome 19q12. Nat Genet 1993;3(3): 256-9.
59. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383(6602):707-10.
60. Vikelis M, Xifaras M, Mitsikostas DD. CADASIL: a short review of the literature and a description of the first family from Greece. Funct Neurol 2006;21(2):77-82.
61. Dichgans M, Wick M, Gasser T. Cerebrospinal fluid findings in CADASIL. Neurology 1999;53(1):233.
62. Razvi SS, Bone I. Single gene disorders causing ischaemic stroke. J Neurol 2006;253(6):685-700.
63. Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995;346(8980):934-9.
64. van den Boom R, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages-3rd-6th decades. Radiology 2003;229(3):683-90.
65. Liem MK, van der Grond J, Haan J, et al. Lacunar infarcts are the main correlate with cognitive dysfunction in CADASIL. Stroke 2007;38(3):923-8.
66. Federico A, Bianchi S, Dotti MT. The spectrum of mutations for CADASIL diagnosis. Neurol Sci 2005;26(2):117-24.
67. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3 ectodomain is a major component of granular osmio-philic material (GOM) in CADASIL. Acta Neuropathol (Berl) 2006;112(3):333-9.
68. Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000;105(5):597-605.
69. Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A. Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke 2005;36(5):1053-8.
70. Yanagawa S, Ito N, Arima K, Ikeda S. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Neurology 2002;58(5):817-20.
71. Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. Ophthalmology 1988;95(5):649-59.
72. Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain 1998;121 (Pt 2):303-16.
73. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997;49(5):1322-30.
74. Vahedi K, Massin P, Guichard J P, et al. Hereditary infantile hemi-paresis, retinal arteriolar tortuosity, and leukoencephalopathy. Neurology 2003;60(1):57-63.
75. Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62(9):885-98.
76. Hagel C, Groden C, Niemeyer R, Stavrou D, Colmant HJ. Subcortical angiopathic encephalopathy in a German kindred suggests an autosomal dominant disorder distinct from CADASIL. Acta Neuropathol (Berl) 2004;108(3):231-40.
77. Tomimoto H, Ohtani R, Wakita H, et al. Small artery dementia in Japan: radiological differences between CADASIL, leukoara-iosis and Binswanger's disease. Dement Geriatr Cogn Disord 2006;21(3):162-9.
78. Vilela P, Goulao A. Ischemic stroke: carotid and vertebral artery disease. Eur Radiol 2005;15(3):427-33.
79. Bendszus M, Koltzenburg M, Burger R, Warmuth-Metz M, Hofmann E, Solymosi L. Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study. Lancet 1999;354(9190):1594-7.
80. Schmiedel J, Jackson S, Schafer J, Reichmann H. Mitochondrial cytopathies. J Neurol 2003;250(3):267-77.
81. McKenzie M, Liolitsa D, Hanna MG. Mitochondrial disease: mutations and mechanisms. Neurochem Res 2004;29(3):589-600.
82. Betts J, Jaros E, Perry RH, et al. Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. Neuropathol Appl Neurobiol 2006;32(4):359-73.
83. Michelson DJ, Ashwal S. The pathophysiology of stroke in mitochondrial disorders. Mitochondrion 2004;4(5-6):665-74.
84. Ohama E, Ohara S, Ikuta F, Tanaka K, Nishizawa M, Miyatake T. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol (Berl) 1987;74(3):226-33.
85. Chomyn A, Enriquez JA, Micol V, Fernandez-Silva P, Attardi G. The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J Biol Chem 2000;275(25):19198-209.
86. Iizuka T, Sakai F, Ide T, Miyakawa S, Sato M, Yoshii S. Regional cerebral blood flow and cerebrovascular reactivity during chronic stage of stroke-like episodes in MELAS-Implication of neurovascular cellular mechanism. J Neurol Sci 2007.
87. Iizuka T, Sakai F, Suzuki N, et al. Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 2002;59(6):816-24.
88. de Vries D, de Wijs I, Ruitenbeek W, et al. Extreme variability of clinical symptoms among sibs in a MELAS family correlated with heteroplasmy for the mitochondrial A3243G mutation. J Neurol Sci 1994;124(1):77-82.
89. Koga Y, Akita Y, Junko N, et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 2006;66(11):1766-9.
90. Krupinski J, Kaluza J, Kumar P, Wang M, Kumar S. Prognostic value of blood vessel density in ischaemic stroke. Lancet 1993;342(8873):742.
91. Heiss WD, Sobesky J, Hesselmann V. Identifying thresholds for penumbra and irreversible tissue damage. Stroke 2004;35(11 Suppl 1):2671-4.
92. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4(11): 1313-7.
93. Steindler DA, Pincus DW. Stem cells and neuropoiesis in the adult human brain. Lancet 2002;359(9311):1047-54.
94. Slevin M, Krupinski J, Kumar P, Gaffney J, Kumar S. Gene activation and protein expression following ischaemic stroke: strategies towards neuroprotection. J Cell Mol Med 2005;9(1):85-102.
95. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 1999;79(4): 417-25.
96. Slevin M, Krupinski J, Slowik A, Kumar P, Szczudlik A, Gaffney J. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 2000;31(8):1863-70.
97. Krupinski J, Issa R, Bujny T, et al. A putative role for plateletderived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 1997;28(3):564-73.
98. Krupinski J, Kumar P, Kumar S, Kaluza J. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke 1996;27(5):852-7.
99. Issa R, AlQteishat A, Mitsios N, et al. Expression of basic fibroblast growth factor mRNA and protein in the human brain following ischaemic stroke. Angiogenesis 2005;8(1):53-62.
100. Mu D, Chang YS, Vexler ZS, Ferriero DM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol 2005; 195(2):407-15.
101. Marti HJ, Bernaudin M, Bellail A, et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 2000;156(3):965-76.
102. van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999;104(11):1613-20.
103. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000;106(7):829-38.
104. Wang Y, Kilic E, Kilic U, et al. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 2005;128(Pt 1):52-63.
105. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113(4): 516-27.
106. Lennmyr F, Ata KA, Funa K, Olsson Y, Terent A. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol 1998;57(9):874-82.
107. Sun Y, Jin K, Xie L, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003;111(12):1843-51.
108. Sun FY, Guo X. Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J Neurosci Res 2005;79(1-2):180-4.
109. Yano A, Shingo T, Takeuchi A, et al. Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. J Neurosurg 2005;103(1):104-14.
110. Zhang ZG, Zhang L, Tsang W, et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 2002;22(4):379-92.
111. Harrigan MR, Ennis SR, Sullivan SE, Keep RF. Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochir (Wien) 2003;145(1):49-53.
112. Hayashi T, Abe K, Itoyama Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 1998;18(8): 887-95.
113. Tonges L, Schlachetzki JC, Weishaupt JH, Bahr M. Hematopoietic cytokines-on the verge of conquering neurology. Curr Mol Med 2007;7(2):157-70.
114. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6.
115. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004;363(9415):1139-46.
116. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349(9046):151-4.
117. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004;35(11 Suppl 1):2616-9.
118. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5(5): 347-60.
119. Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 2004;26(5):573-8.
120. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28(4):202-8.
121. Chapuis J, Tian J, Shi J, et al. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. Neurobiol Aging 2006;27(9):1212-5.
122. Del Bo R, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 2005;57(3):373-80.
123. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 1998;62(1):101-5.
124. Vagnucci AH, Jr., Li WW. Alzheimer's disease and angiogenesis. Lancet 2003;361(9357):605-8.
125. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis 2006;10(1):111-8.
126. Siedlak SL, Cras P, Kawai M, Richey P, Perry G. Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. J Histochem Cytochem 1991;39(7):899-904.
127. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 2004;25(3):283-90.
128. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10 Suppl 1:S3-7.
129. Barcia C, Emborg ME, Hirsch EC, Herrero MT. Blood vessels and parkinsonism. Front Biosci 2004;9:277-82.
130. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999;353(9157):981-2.
131. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000;425(4): 479-94.
132. Yoshimi K, Ren YR, Seki T, et al. Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol 2005;58(1):31-40.
133. Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 2003;100(13):7925-30.
134. Wada K, Arai H, Takanashi M, et al. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. Neuroreport 2006;17(7):705-9.
135. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99(18): 11946-50.
136. Pitzer MR, Sortwell CE, Daley BF, et al. Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells. Exp Neurol 2003;182(2):435-45.
137. Yasuhara T, Shingo T, Kobayashi K, et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 2004;19(6):1494-504.
138. Yasuhara T, Shingo T, Muraoka K, et al. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res 2005;1038(1):1-10.
139. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001;24(12):719-25.
140. Haussermann P, Kuhn W, Przuntek H, Muller T. Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease. Neurosci Lett 2001;300(3):182-4.
141. Carvey PM, Zhao CH, Hendey B, et al. 6-Hydroxydopamineinduced alterations in blood-brain barrier permeability. Eur J Neurosci 2005;22(5):1158-68.
142. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57(2):176-9.
143. Westin JE, Lindgren HS, Gardi J, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006;26(37):9448-61.
144. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52.
145. Rindfleisch E. Pathological Histology: An Introduction to the Study of Pathlogical Anatomy (translated by Kloman, W.C. and Miles F.T.): Trubner & Co.; 1872.
146. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354(9): 942-55.
147. Tan IL, van Schijndel RA, Pouwels PJ, et al. MR venography of multiple sclerosis. AJNR Am J Neuroradiol 2000;21(6): 1039-42.
148. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002;12(2):154-69.
149. Kirk S, Frank JA, Karlik S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J Neurol Sci 2004;217(2):125-30.
150. Rashid W, Parkes LM, Ingle GT, et al. Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75(9):1288-93.
151. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002;61(10):914-25.
152. Wuerfel J, Bellmann-Strobl J, Brunecker P, et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004;127 (Pt 1):111-9.
153. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 1997;75(3):165-73.
154. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 2000;50(1-2):139-48.
155. Giovannoni G, Miller DH, Losseff NA, et al. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol 2001;248(6):487-95.
156. Su JJ, Osoegawa M, Matsuoka T, et al. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2006;243(1-2):21-30.
157. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198(3):483-9.
158. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004;172(7):4618-23.
159. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23(2-3):263-72.
160. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101(12):4878-86.
161. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26(9):943-54.
162. Jin K, Mao XO, Greenberg DA. Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol 2006;66(3): 236-42.
163. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55(18):4140-5.
164. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J 2000;6 Suppl 2:S134-41.
165. Lindner DJ, Borden EC. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res 1997;17(11):681-93.
166. Colville-Nash PR, Alam CA, Appleton I, Brown JR, Seed MP, Willoughby DA. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J Pharmacol Exp Ther 1995;274(3):1463-72.
167. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221(4612):719-25.
168. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341(2-3):309-15.
169. Billington DC. Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases. Drug Des Discov 1991;8(1):3-35.
170. Hommes OR, Weiner HL. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis. Mult Scler 2002;8(2):139-41.
171. Polverini PJ, Novak RF. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. Biochem Biophys Res Commun 1986;140(3):901-7.
172. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361(9374):2059-67.
173. Vortmeyer AO, Frank S, Jeong SY, et al. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 2003;63(21):7051-5.
174. Zec N, Cera P, Towfighi J. Extramedullary hematopoiesis in cerebellar hemangioblastoma. Neurosurgery 1991;29(1): 34-7.
175. Park DM, Zhuang Z, Chen L, et al. von Hippel-Lindau Disease-Associated Hemangioblastomas Are Derived from Embryologic Multipotent Cells. PLoS Med 2007;4(2):e60.
176. Huber TL, Kouskoff V, Fehling HJ, Palis J, Keller G. Haeman-gioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 2004;432(7017):625-30.
177. Glasker S, Li J, Xia JB, et al. Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res 2006;66(8):4167-72.
178. Samuelsen SO, Bakketeig LS, Tretli S, Johannesen TB, Magnus P. Head circumference at birth and risk of brain cancer in childhood: a population-based study. Lancet Oncol 2006;7(1): 39-42.
179. Trichopoulos D, Lagiou P, Adami HO. Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissue-specific stem cells. Breast Cancer Res 2005;7(1):13-7.
180. van Eekelen JA, Bradley CK, Gothert JR, et al. Expression pattern of the stem cell leukaemia gene in the CNS of the embryonic and adult mouse. Neuroscience 2003;122(2):421-36.
181. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15(1):29-41.
182. Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothe-lial growth factor receptor inhibitor su5416. Ophthalmology 2002;109(9):1745-51.
183. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995;15(3):339-47.
184. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77(2):362-72.
185. Kieran MW. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat Res 2004;117:337-49.
186. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438(7070):932-6.
187. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004;18(2):338-40.
188. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61(18):6624-8.
189. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56(9):2185-90.
190. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery 2004;55(3):562-7; discussion 7-8.
191. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106(9):3058-61.
192. Louissaint A, Jr., Rao S, Leventhal C, Goldman SA. Coordinated
193. Mukouyama YS, Shin D, Britsch S, Taniguchi M, Anderson DJ. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 2002;109(6): 693-705.
194. Johnston M. The importance of lymphatics in cerebrospinal fluid transport. Lymphat Res Biol 2003;1(1):41-4; discussion 5.
195. Zakharov A, Papaiconomou C, Johnston M. Lymphatic vessels gain access to cerebrospinal fluid through unique association with olfactory nerves. Lymphat Res Biol 2004;2(3):139-46.
196. Zhang J, Williams MA, Rigamonti D. Genetics of human hydro-cephalus. J Neurol 2006;253(10):1255-66.
197. Lambrechts D, Devriendt K, Driscoll DA, et al. Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study. J Med Genet 2005;42(6):519-22.
198. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34(4):383-94.
199. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28(2):131-8.
200. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8(1): 85-92.
201. Kouznetsova E, Klingner M, Sorger D, et al. Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int J Dev Neurosci 2006;24(2-3):187-93.
202. Krupinski J, Stroemer P, Slevin M, Marti E, Kumar P, Rubio F. Three-dimensional structure and survival of newly formed blood vessels after focal cerebral ischemia. Neuroreport 2003;14(8):1171-6.